2. Search Result
Search Result
Results for "

IgG1λ

" in MedChemExpress (MCE) Product Catalog:

15

Inhibitors & Agonists

19

Inhibitory Antibodies

3

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P99039
    Oleclumab

    MEDI9447

    		 CD73 Cancer
    Oleclumab (MEDI9447) is a human IgG1λ monoclonal antibody targeting CD73 and inhibits the exonuclease activity of the extracellular enzyme CD73. Oleclumab can adjust the composition of bone marrow and lymphoid infiltrating leukocyte populations in the tumor microenvironment and has anti-tumor activity [1] .
    Oleclumab
  • HY-P9952
    Belimumab
    2 Publications Verification

    LymphoStat B

    		 TNF Receptor CD20 Inflammation/Immunology Cancer
    Belimumab (LymphoStat B) is a humanized IgG1λ monoclonal antibody against B-lymphocyte stimulator (BLyS) protein. Belimumab antagonizes BLyS activity in autoimmune diseases and B-lymphocyte malignancies. Belimumab can be used for systemic lupus erythematosus (SLE) research [1] .
    Belimumab
  • HY-P99322
    Tesidolumab

    LFG316; Anti-Human C5 Recombinant Antibody

    		 Complement System Inflammation/Immunology
    Tesidolumab (LFG316) is a fully-human IgG1/λ anti-C5 monoclonal antibody of 143 kDa (without glycosylation). Tesidolumab (LFG316) blocks cleavage of C5 and prevents subsequent formation of the membrane attack complex [1].
    Tesidolumab
  • HY-P99588
    Stamulumab

    MYO-029

    		 TGF-β Receptor Metabolic Disease
    Stamulumab (MYO-029) is a recombinant human IgG1λ antibody that binds to myostatin and neutralizes its activity by preventing binding to its endogenous high-affinity receptor ActRIIB. Stamulumab leads to muscle fiber hypertrophy and not hyperplasia in SCID mice. Stamulumab has the potential for Becker muscular dystrophy (BMD), facioscapulohumeral dystrophy (FSHD), and limb-girdle muscular dystrophy (LGMD) research [1] .
    Stamulumab
  • HY-P99621
    Fiztasovimab

    NPC-21; EV2038

    		 CMV Infection
    Fiztasovimab (NPC-21; EV2038) is a fully human IgG1λ mAb against human cytomegalovirus (hCMV). Fiztasovimab acts neutralizing activity by binding to the antigenic domain 1 of glycoprotein B on hCMV envelope. Fiztasovimab inhibits cell-to-cell transmission of hCMV [1].
    Fiztasovimab
  • HY-P99730
    Mezagitamab

    TAK-079

    		 CD38 Cancer
    Mezagitamab (TAK-079) is a IgG1λ anti-CD38 monoclonal antibody. Mezagitamab depletes tumor cells expressing CD38 through antibody and complement dependent cytotoxicity. Mezagitamab has potential application in relapsed/refractory multiple myeloma (RRMM) and idiopathic thrombocytopenic purpura (ITP) [1] .
    Mezagitamab
  • HY-P990016
    Temtokibart

    		Interleukin Related Inflammation/Immunology
    Temtokibart is a humanized IgG1λ2 antibody targeting IL22RA1. Expressed by cells lacking the glutamine synthetase gene.
    Temtokibart
  • HY-P990015
    Tobevibart

    		HBV Infection
    Tobevibart is an IgG1-lambda, anti-HBV (hepatitis B virus) surface envelope protein human monoclonal antibody. Tobevibart shows antiviral activity [1].
    Tobevibart
  • HY-P990014
    Danburstotug

    IMC-001; STI-3031

    		 PD-1/PD-L1 Inflammation/Immunology Cancer
    Danburstotug (IMC-001) is an IgG1-lambda anti-CD274 (PDL1, B7 homologue 1, B7H1) human monoclonal antibody. Danburstotug also is immunostimulant and antineoplastic [1].
    Danburstotug
  • HY-P99871
    Ebronucimab

    AK102

    		 PCSK9 Others
    Ebronucimab (AK102) is an IgG1-λ2 antibody targeting PCSK9 and is primarily expressed by CHO DG44 (Chinese Hamster Ovary) cells [1].
    Ebronucimab
  • HY-145641
    Crexavibart

    BMS-986413; C-144-LS

    		 SARS-CoV Infection
    Crexavibart (BMS-986413; C-144-LS) is an IgG1λ2 antibody that targets the SARS-CoV2 spike (S) glycoprotein receptor-binding domain [1].
    Crexavibart
  • HY-P99102
    Zinlirvimab

    10-1074

    		 HIV Infection
    Zinlirvimab is a human IgG1-λ2, HIV neutralising antibody targeting to HIV-1 gp120 envelope glycoprotein (IIIB gp120 V3 loop) [1] .
    Zinlirvimab
  • HY-P99103
    Bebtelovimab

    LY-3853113; LY-COV1404

    		 SARS-CoV Infection
    Bebtelovimab a humanized IgG1-λ2 antibody targeting to SARS-CoV-2, especially COVID-19. Bebtelovimab potently neutralizes SARS-CoV-2 variants, and inhibits COVID-19 with mild-to-moderate efficacy [1] .
    Bebtelovimab
  • HY-P990006
    Duvakitug

    		TNF Receptor Inflammation/Immunology
    Duvakitug is a humanized IgG1-λ2 monoclonal antibody targeting to TNFSF15/TL1A. Duvakitug' main expression system is CHOK1SV cells endogenously expressing glutamine synthetase (GS). Duvakitug can be used in the study of Crohn's Disease (CD) [1] .
    Duvakitug
  • HY-P99293
    Galiximab

    IDEC 114; Anti-Human CD80 Recombinant Antibody

    		 CD28 Cancer
    Galiximab (IDEC 114) is a primatized immunoglobulin G1 (IgG1) lambda monoclonal antibody directed against the CD80 antigen and blocks CD80–CD28 binding. Galiximab has variable regions are primatized (cynomologous monkeys), and the constant regions are human. Galiximab can be used in research of B-cell lymphoma [1].
    Galiximab

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: